RTx-303

• Description :

  RTx-303 is an orally active, selective DNA polymerase θ (Polθ) inhibitor (IC50 = 5.1 nM) . RTx-303 exhibits significantly high cellular potency and strongly potentiates PARPi in BRCA1/2 mutant cells and patient-derived xenograft models. RTx-303 can be used for the study of BRCA2-mutated breast cancer[1].

• CAS Number :

  [3035072-99-9]

• UNSPSC :

  12352005

• Target :

  DNA/RNA Synthesis

• Related Pathways :

  Cell Cycle/DNA Damage

• Field of Research :

  Cancer

• Smiles :

  CN(C)C[C@@H](O)CN(C1=O)CCN1C2=C(OC(N(C([2H])([2H])[2H])C3=CC=C(F)C=C3)=O)C(C(F)(F)F)=CC(C(F)(F)F)=C2

• Molecular Formula :

  C24H22D3F7N4O4

• Molecular Weight :

  569.49

• References & Citations :

  [1]Chandramouly G, et al. RTx-303, an Orally Bioavailable Polθ Polymerase Inhibitor That Potentiates PARP Inhibitors in BRCA Mutant Tumors. J Med Chem. 2025 Nov 13;68 (21) :22196-22215.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported